What the Court Decided
A federal judge has ruled that the FDA did not adequately explain why it kept certification requirements on prescribers and pharmacies dispensing mifepristone, given that the agency has repeatedly concluded over 25 years that the drug is safe and effective.
Judge Robert Ballou of the U.S. District Court for the Western District of Virginia issued the 48-page opinion on July 23 in a case brought by Whole Woman's Health, described in the ruling as a group of health care providers and clinicians who prescribe the drug. Ballou held that the 2023 modifications to the drug's safety program are arbitrary and capricious under the Administrative Procedure Act.
The decision is narrower than the headline suggests, in two directions. Ballou dismissed the plaintiffs' separate claim that the agency exceeded its statutory authority. And he declined to vacate the requirements, instead sending the matter back to the FDA to reconsider.
The practical effect for patients and clinicians today is none. The certification requirements remain in force while the agency reviews them.
What a REMS Is and What the 2023 Version Requires
A risk evaluation and mitigation strategy, known as a REMS, is a program the FDA can impose on a drug when the agency determines that additional measures are needed to ensure its benefits outweigh its risks. It is not a judgment that a drug is dangerous. It is a set of conditions attached to how a drug is prescribed, dispensed, or monitored, and hundreds of medications carry some version of one.
The strongest components are called elements to assure safe use. The 2023 mifepristone REMS contains three. The FDA removed the requirement that the drug be dispensed in person, and retained a prescriber certification requirement and a patient agreement form. It added certification requirements for pharmacies that dispense it.
According to the court's opinion, the stated goal of the 2023 program is "to mitigate the risk of serious complications associated with mifepristone."
Mifepristone was approved in 2000 and is used with a second drug, misoprostol, in the most common medication abortion regimen in the United States.
The Gap the Judge Identified
The ruling turns on a question of administrative reasoning rather than medicine, and the distinction matters for how readers should interpret it.
Ballou wrote that the agency's 2023 rationale "does not identify the risk alleviated by the restrictions." The opinion notes that the FDA has consistently found the drug safe and effective across a quarter century, and observes that the agency did not explain how, absent these restrictions, prescribing would become an intolerable risk of the kind that would justify removing the drug from the market altogether.
The court also found that the FDA relied on projected increases in provider volume to justify retaining the prescriber certification and patient agreement requirements, without connecting provider volume to a factor the statute directs it to consider.
Ballou was explicit about the limits of his own review. The opinion states that the court does not assess whether the requirements are in fact necessary to ensure the drug's benefits outweigh its risks. It examines only whether the agency's decision-making process provided an adequate basis for its conclusions, and concludes that the analysis fell short of explaining the reasoning behind them.
That is the standard courts apply to agency action generally, and a finding of inadequate explanation is not a finding that the opposite conclusion is correct.
What the Ruling Does Not Do
Several things did not happen, and each is easy to lose in summaries.
The requirements were not struck down. Prescriber and pharmacy certification and the patient agreement form remain in effect. The agency was not ordered to reach any particular outcome, only to reconsider and explain. The court did not rule that the FDA lacks authority to impose a REMS on this drug, having dismissed that claim.
The ruling also does not resolve the broader litigation. Separate cases brought by states, including Louisiana, challenge the 2023 changes from the opposite direction, arguing the agency was wrong to relax the in-person dispensing requirement. A federal appeals court granted a stay in that litigation earlier this year, and the Supreme Court in May allowed the mail dispensing policy to remain in effect while a challenge is paused pending the FDA's own review. A parallel federal court decision in a separate case also found the 2023 program inadequately justified and likewise declined to vacate it.
The result is that two sets of plaintiffs are asking courts to send the same rule back to the agency for incompatible reasons, and the agency has not yet responded to either.
What Happens Next
The FDA has a safety review of mifepristone underway. A senior agency official confirmed in June that the review was proceeding and could be completed within months. The agency has said that if it determines changes to the program are warranted, it will take appropriate action.
That review is now the point where these threads converge. Whatever the FDA produces will have to address the reasoning gap Ballou identified, and will be read closely by parties on both sides of the litigation.
Several questions remain open. The agency has not said when its review will conclude, whether it will modify the program, or how it will respond to the remand. Whether the ruling is appealed is also unresolved.
For patients, nothing about access or dispensing changed on July 23. Anyone with questions about a prescription should raise them with the prescribing clinician or pharmacist rather than drawing conclusions from litigation coverage, since requirements vary by state independent of federal rules. Nobody should change or stop a prescribed medication based on a court ruling.
The newest confirmed fact is that a federal court found the 2023 requirements inadequately justified and remanded them. Those most immediately affected are the FDA and the clinicians and pharmacies subject to certification. The reasonable action for patients is none, since the rules are unchanged. The central uncertainty is what the agency's pending safety review concludes. The next expected development is the completion of that review.
Frequently Asked Questions
What did the judge actually rule? That the FDA's 2023 modifications to the mifepristone safety program were arbitrary and capricious because the agency did not adequately explain its reasoning.
Did the requirements get struck down? No. The judge declined to vacate them and sent the matter back to the FDA. Prescriber and pharmacy certification remain in effect.
What is a REMS? A risk evaluation and mitigation strategy, a set of conditions the FDA can attach to how a drug is prescribed or dispensed. Many medications carry one.
Did the court say the drug is safe or unsafe? Neither. The court explicitly declined to assess whether the requirements are necessary, reviewing only whether the agency explained its decision adequately.
Did the plaintiffs win everything they asked for? No. The judge dismissed their claim that the FDA exceeded its statutory authority, and did not vacate the rule.
Does anything change for patients now? No. The requirements remain in force. Questions about a specific prescription belong with a prescribing clinician or pharmacist.
What happens next? The FDA has a safety review underway that an official said in June could finish within months. The agency has not said what it will conclude.
